A brain-derived neurotrophic factor polymorphism Val66Met identifies fibromyalgia syndrome subgroup with higher body mass index and C-reactive protein

Yangming Xiao, I. Jon Russell, Ya-guang Liu

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Original languageEnglish
Pages (from-to)2479-2485
Number of pages7
JournalRheumatology International
Volume32
Issue number8
DOIs
StatePublished - Aug 2012

Fingerprint

Fibromyalgia
Brain-Derived Neurotrophic Factor
C-Reactive Protein
Body Mass Index
Single Nucleotide Polymorphism
Valine
Methionine
Phenotype
Pain Threshold
Sleep Initiation and Maintenance Disorders
Serum
Restriction Fragment Length Polymorphisms
Genes
Enzyme-Linked Immunosorbent Assay
Genotype
Depression

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

A brain-derived neurotrophic factor polymorphism Val66Met identifies fibromyalgia syndrome subgroup with higher body mass index and C-reactive protein. / Xiao, Yangming; Russell, I. Jon; Liu, Ya-guang.

In: Rheumatology International, Vol. 32, No. 8, 08.2012, p. 2479-2485.

Research output: Contribution to journalArticle

@article{12e6064c281d4ae0840af585465c81d9,
title = "A brain-derived neurotrophic factor polymorphism Val66Met identifies fibromyalgia syndrome subgroup with higher body mass index and C-reactive protein",
abstract = "A common single nucleotide polymorphism (SNP) in the gene of brain-derived neurotrophic factor (BDNF) results from a substitution at position 66 from valine (Val) to methionine (Met) and may predispose to human neuropsychiatric disorders. We proposed to determine whether these BDNF gene SNPs were associated with fibromyalgia syndrome (FMS) and/or any of its typical phenotypes. Patients with FMS (N = 95) and healthy normal controls (HNC, N = 58) were studied. Serum highsensitivity C-reactive protein (hsCRP) levels were measured using an enzyme-linked immunosorbent assay (ELISA). The BDNF SNPs were determined using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The BDNF SNP distribution was 65 (68{\%}) Val/Val, 28 (30{\%}) Val/Met, and 2 (2{\%}) Met/Met for FMS and 40 (69{\%}), 17(29{\%}), and 1 (2{\%}) for HNC, respectively. The serum high-sensitivity C-reactive protein (hsCRP)and body mass index (BMI) in FMS were higher than in HNC. The FMS with BDNF Val66Val had significantly higher mean BMI (P = 0.0001) and hsCRP (P = 0.02) than did FMS carrying the Val66Met genotype. This pattern was not found in HNC. Phenotypic measures of subjective pain, pain threshold, depression, or insomnia did not relate to either of the BDNF SNPs in FMS. The relative distribution BDNF SNPs did not differ between FMS and HNC. The BDNF Val66Met polymorphism is not selective for FMS. The BDNF Val66Val SNP identifies a subgroup of FMS with elevated hsCRP and higher BMI. This is the first study to associate a BDNF polymorphism with a FMS subgroup phenotype.",
keywords = "Body mass index, Brain-derived neurotrophic factor, C-reactive protein, Fibromyalgia syndrome, Single nucleotide polymorphism",
author = "Yangming Xiao and Russell, {I. Jon} and Ya-guang Liu",
year = "2012",
month = "8",
doi = "10.1007/s00296-011-1990-z",
language = "English",
volume = "32",
pages = "2479--2485",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - A brain-derived neurotrophic factor polymorphism Val66Met identifies fibromyalgia syndrome subgroup with higher body mass index and C-reactive protein

AU - Xiao, Yangming

AU - Russell, I. Jon

AU - Liu, Ya-guang

PY - 2012/8

Y1 - 2012/8

N2 - A common single nucleotide polymorphism (SNP) in the gene of brain-derived neurotrophic factor (BDNF) results from a substitution at position 66 from valine (Val) to methionine (Met) and may predispose to human neuropsychiatric disorders. We proposed to determine whether these BDNF gene SNPs were associated with fibromyalgia syndrome (FMS) and/or any of its typical phenotypes. Patients with FMS (N = 95) and healthy normal controls (HNC, N = 58) were studied. Serum highsensitivity C-reactive protein (hsCRP) levels were measured using an enzyme-linked immunosorbent assay (ELISA). The BDNF SNPs were determined using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The BDNF SNP distribution was 65 (68%) Val/Val, 28 (30%) Val/Met, and 2 (2%) Met/Met for FMS and 40 (69%), 17(29%), and 1 (2%) for HNC, respectively. The serum high-sensitivity C-reactive protein (hsCRP)and body mass index (BMI) in FMS were higher than in HNC. The FMS with BDNF Val66Val had significantly higher mean BMI (P = 0.0001) and hsCRP (P = 0.02) than did FMS carrying the Val66Met genotype. This pattern was not found in HNC. Phenotypic measures of subjective pain, pain threshold, depression, or insomnia did not relate to either of the BDNF SNPs in FMS. The relative distribution BDNF SNPs did not differ between FMS and HNC. The BDNF Val66Met polymorphism is not selective for FMS. The BDNF Val66Val SNP identifies a subgroup of FMS with elevated hsCRP and higher BMI. This is the first study to associate a BDNF polymorphism with a FMS subgroup phenotype.

AB - A common single nucleotide polymorphism (SNP) in the gene of brain-derived neurotrophic factor (BDNF) results from a substitution at position 66 from valine (Val) to methionine (Met) and may predispose to human neuropsychiatric disorders. We proposed to determine whether these BDNF gene SNPs were associated with fibromyalgia syndrome (FMS) and/or any of its typical phenotypes. Patients with FMS (N = 95) and healthy normal controls (HNC, N = 58) were studied. Serum highsensitivity C-reactive protein (hsCRP) levels were measured using an enzyme-linked immunosorbent assay (ELISA). The BDNF SNPs were determined using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The BDNF SNP distribution was 65 (68%) Val/Val, 28 (30%) Val/Met, and 2 (2%) Met/Met for FMS and 40 (69%), 17(29%), and 1 (2%) for HNC, respectively. The serum high-sensitivity C-reactive protein (hsCRP)and body mass index (BMI) in FMS were higher than in HNC. The FMS with BDNF Val66Val had significantly higher mean BMI (P = 0.0001) and hsCRP (P = 0.02) than did FMS carrying the Val66Met genotype. This pattern was not found in HNC. Phenotypic measures of subjective pain, pain threshold, depression, or insomnia did not relate to either of the BDNF SNPs in FMS. The relative distribution BDNF SNPs did not differ between FMS and HNC. The BDNF Val66Met polymorphism is not selective for FMS. The BDNF Val66Val SNP identifies a subgroup of FMS with elevated hsCRP and higher BMI. This is the first study to associate a BDNF polymorphism with a FMS subgroup phenotype.

KW - Body mass index

KW - Brain-derived neurotrophic factor

KW - C-reactive protein

KW - Fibromyalgia syndrome

KW - Single nucleotide polymorphism

UR - http://www.scopus.com/inward/record.url?scp=84866264615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866264615&partnerID=8YFLogxK

U2 - 10.1007/s00296-011-1990-z

DO - 10.1007/s00296-011-1990-z

M3 - Article

C2 - 21773883

AN - SCOPUS:84866264615

VL - 32

SP - 2479

EP - 2485

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 8

ER -